Abstract
Colin Anderson / Getty Images
Precision oncology company Strata Oncology announced the addition of five healthcare systems to the Strata Precision Oncology Network. The network, launched early last year, aims to provide patients with advanced cancer routine tumor profiling with the goal of matching them to active clinical trials.
New networks members are University of Wisconsin Carbone Cancer Center, Christiana Care's Helen F. Graham Cancer Center & Research Institute, Kaiser Permanente-Northern California, Kettering Health Network, and Ochsner Health System.
“With the addition of new partners to the network, we are well on our way to our goal of providing tumor profiling to 25,000 advanced cancer patients annually,” said Dan Rhodes, Ph.D., CEO of Strata Oncology. “We are proud to work with these forward-thinking centers to institutionalize tumor profiling and dramatically expand patient access to precision oncology.”
Network members provide no-cost testing to patients using the StrataNGS test, an 87-gene assay that allows for the sequencing of both DNA and RNA. The testing is part of the Strata Trial, a nationwide observational study providing tumor sequencing for 100,000 patients with advanced cancer.
“This clinical trial will allow us to offer routine, no-cost tumor sequencing to patients with advanced cancer,” said Mark E. Burkard, M.D., Ph.D., associate professor at University of Wisconsin. “By addressing key barriers to patient participation, we hope to enable increased access to precision medicine clinical trials.”